Emmanuelle Charpentier of the Helmholtz Centre for Infection Research and Jennifer Doudna of the University of California, Berkeley, are pioneers in the field of a genome editing technique known as CRISPR, but the first U.S. patent was awarded to Feng Zhang, Doudna's partner at startup Editas Medicine. Charpentier, who founded CRISPR Therapeutics, says she retains some intellectual property rights. Doudna says the platform allows multiple players.

Related Summaries